Skin CancerNCT05033678
Implementation of Teledermoscopy and Artificial Intelligence
An observational study of Skin Cancer, run by Region Skane at 1 site in Sweden.
Trial summary
The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic accuracy in general practitioners. Read more about this study
- Who is it for?
- Ages 15 years and olderHealthy volunteers can take part
- Conditions the study is for
- Skin Cancer
- What is being tested?
- Diagnostic algorithms
- Type of treatment
- Medical device
- How many people
- 8,000 participants
- Where
- 1 siteSweden
- Study dates
- 16 Aug 2021to 31 Aug 2029
- How long will I take part?
- 8 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: All patients, 15 years or older, seeking care for a suspected skin lesion, or when a suspected skin lesion is detected during a visit for another complaint, for whom a teledermoscopic consultation is created.
Who may be able to join
- Has a skin lesion assessed by a physician during a visit
- The physician decides to create a teledermoscopy referral
Who cannot join
- inability or unwillingness to participate in the study
- the patient is younger than 15 years old
- Images of such bad quality they cannot be assessed
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Department of dermatology, Skane University Hospital
Lund, 22185
Asa Ingvar, PhD, +46046172243, asa.ingvar@skane.se
About this study
Official title: Teledermoscopy and Artificial Intelligence: Effects of Implementation in Clinical Practice
The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic accuracy in general practitioners.
Part 2 will create artificial intelligence (AI) as support tools for teledermocsopic assessors and investigate the effect of introducing AI within teledermocsopy. In this study the investigators will measure the diagnostic accuracy of teledermoscopic assessors that had access to the results of artificial intelligence algorithm compared to those who did not.
Data will be collected through teledermoscopic referrals, patient records, national registries and questionnairs.
Read the detailed description
Study objective:
- Is teledermoscopy an equally safe method as conventional care for skin cancer patients? 2. How should teledermoscopy be performed and by whom? 2. How does teledermoscopy affect current care and organization of skin diseases? 3. Can deep learning AI improve diagnostic accuracy by being a diagnostic support to dermatologists? 4. How should AI be implemented in care pathways for optimal interaction between assessors and AI?
Material and methods:
- Study setting Patients scheduled for a skin examination for a suspected skin lesion can be recruited, both in dermatology clinics and participating primary care clinics or digitally after visiting primary health clinics.
- Data acquisition Patient data and images will be collected with the Dermicus® application. Participating PCP and dermatologists will also fill in a questionnaire about their assessment of the patient. Additional informaiton will be collected from medical records, i.e. histopathological diagnoses, and from national registries. Questionnaires will be entered in a digital data base using REDCap®.
- Statistical analyses 4.1. In part 1, the number of consultations send to dermatologists and for pathological analyses before introduction of teledermoscopy and during the first and second year if using teledermoscopy will be analysed. Descriptive statistics will be presented and differences between the different time periods will be tested with t-tests and paired t-tests.
Additionally, other aspects of teledermatology will be examined, such as the impact on diagnostic accuracy of performing double-reader instead of singe-reader assessments as well as the propensity in primary care physicians to perform total body skin examinations when using teledermoscopy instead of traditional referals to dermatologists for the assessment of skin lesions.
4.2. Also part 2 has several substudies which focus on the impact of diagnostic accuracy and clinical management when introducing AI that perform different tasks in the teledermocopy work flow. For example, one AI will be trained to categorise all skin lesions referred through teledermoscopy in eight diagnostic categories and another will be looking at finer-grained diagnostic classes, such as subclassification of basal cell carcinoma.
Measures of diagnostic accuracy will be estimated comparing dermatologists with and without access to diagnostic algorithm support. Measures reported include sensitivity, specificity, and Area under ROC-curve (AUROC). Part 2 The study will also report in detail the impact the AI has on the willingness to change a diagnosis or a management plan (in all directions).
Generalized linear mixed-effects models (GLMMs) with a binomial distribution and logit link function will be used to assess the impact of AI assistance on diagnostic accuracy and management decisions. The models will include AI assistance, patient age, sex, and diagnostic confidence as fixed effects, with random intercepts for individual assessors to account for clustering of observations within assessors.
- Power set to 0.8 and significance to 0.05. 10% censures. 5.1. Patients recruited to this study can be used in several of the sub-studies. The aim of the study is to collect 8000 patients in total in this study.
5.2. To detect a difference in "unimaged skin cancers" between teledermoscopy and conventional care of patients 1200 cases and 2400 controls need to be included.
5.3. To detect a 10% difference in sensitivity/ specificity of diagnostic ability in PCPs before and after working with teledermoscopy 3400 patients need to be included.
5.4. To investigate how artificial intelligence should be implemented in clinical care the investigators have calculated that 6000 patients are needed to detect a 10% difference in sensitivity and specificity in the subgroups.
Ethical considerations and data management:
Data will be collected using Dermicus®, a CE-certified digital platform and mobile application. With the application downloaded on iPhones®, locked for any other uses, the history of the patients are registered. Then, by connecting the iPhone to a dermoscope, macroscopic and dermoscopic images are captured. All data will be stored on the servers of the health care region of Skåne, where the studies are conducted. Once a case has been created and sent to the data base all information will be deleted from the iPhone®. Additional data will also be retrieved from relevant medical records, e.g. histopathological diagnosis, and manually registered in an electronic database at a highly secure location (LUSEC/ REDCap provided by Lund University/ ShareFile provided by Region Skåne) . Data collected from PCP and dermatologists by questionnaires will also be registered in this data base by means of electronic surveys (REDCap). Information from primary care on total number of visits, referrals to dermatologists and referrals to pathology regarding skin lesions will be extracted from patient administrative systems. Age- and sex matched controls will be used for the study investigating missed skin cancer. These controls will be randomly selected from patients that was referred to a skin clinic by paper referral during the same period as the teledermoscopically referred patients were gathered. Algorithms for skin cancer diagnosis will be implemented in the web platform of Dermicus for the studies of introduction of artificial intelligence. Teledermoscopic assessors will be instructed on when and how to use these different tools.
Every month the newly entered data will be checked for completeness, and in the case of missing data, reminders to participating investigators will be send.
When the data sets are complete, identifiers (such as personal identification number) will be replaced by a code kept secure at a different location than the data set. Data will thereafter be extracted from the data base to perform statistical analysis.
The study is approved by the Swedish Ethical Review Authority and all relevant approvals for data extraction and data storage has been obtained.
- Conditions
- Skin Cancer
- Being tested
- Diagnostic algorithms
- Keywords
- Melanoma, non-melanoma skin cancer, teledermoscopy, artificial intelligence, health care organization
- Medical subject headings
- Skin Neoplasms, Melanoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic algorithmsDevice
Assessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case.
What is being measured
The primary outcome is the main question the study is designed to answer.
Effect on referral patterns
Measure how referral patterns are affected by the introduction of teledermoscopy
Measured: 2 years
Effect on diagnostic accuracy due to availability of artificial intelligence
Measuring if the diagnostic accurcy differs depending on if physician can see the results of the artificial intelligence.
Measured: 8 years
Risk of undetected skin cancer
Measuring if the risk of undetected skin cancer increases with the use of teledermoscopy
Measured: 2 years
Artificial intelligence timing and effect on diagnostic accuracy and willingness to rethink the preliminary diagnosis
Measuring if the diagnostic accuracy and the willingness to reconsider the preliminary diagnosis differs according to when in the process a physician is presented with the results of the artificial intelligence
Measured: 8 years
Secondary outcomes (2)
Image enhancement techniques in teledermoscopy
We will investigate whether the use of image enhancements in teledermoscopy affects the diagnostic accuracy in teledermaoscopy
Measured: From 2021 to 2025
When single reader evaluations are insufficient in teledermoscopy
We will investigate if there are special situations when single reader evaluations are insufficient in teledermoscopy
Measured: 2021-2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Sep 2021
- Study start16 Aug 2021
- Primary completion31 Aug 2029 (estimated)
- Study completion31 Aug 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Skin CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 8,000 participants (estimated)
- Target duration
- 8 Years
Sponsor and investigators
- Lead sponsor
- Region Skane
- Sponsor type
- University, hospital or other
- Collaborators
- Lund University, Karolinska University Hospital
- Responsible party
- Sponsor
- Investigators
- Asa Ingvar, PhD, Principal investigator, Department of Dermatology, Skane University Hospital, Region Skane, Sweden
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05033678
- Sponsor's protocol ID
- 2020-04763
- Status last verified
- Oct 2026
- First submitted
- 27 Aug 2021
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Natterdahl C, Kristensson H, Persson B, Lapins J, Ivert LU, Radros N, Schultz K, Sand C, Lundgren S, Pahlow Mose A, Ingvar J, Dizdarevic A, Nielsen K, Ingvar A. When Are Single Reader Evaluations Insufficient in Teledermoscopic Assessments? Analyses of a Retrospective Cohort Study. Telemed J E Health. 2025 May;31(5):579-589. doi: 10.1089/tmj.2024.0532. Epub 2025 Jan 27.
PubMed 39869017
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Teledermoscopy and Artificial Intelligence: Effects of Implementation in Clinical Practice
- ClinicalTrials.gov ID
- NCT05033678
- Acronym / sponsor ID
- 2020-04763
- Conditions
- Skin Cancer
- Keywords
- Melanoma, non-melanoma skin cancer, teledermoscopy, artificial intelligence, health care organization
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 8,000 participants (estimated)
- Lead sponsor
- Region SkaneUniversity, hospital or other
- Collaborators
- Lund University, Karolinska University Hospital
- Study start
- 16 Aug 2021 (actual)
- Primary completion
- 31 Aug 2029 (estimated)
- Study completion
- 31 Aug 2029 (estimated)
- First posted
- 5 Sep 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The study has 2 parts. Part 1 will investigate the effects of introducing teledermoscopy in clinical practice, more specifically the change in referral patterns, the risk of undetected skin cancers and the effect on diagnostic accuracy in general practitioners.
Part 2 will create artificial intelligence (AI) as support tools for teledermocsopic assessors and investigate the effect of introducing AI within teledermocsopy. In this study the investigators will measure the diagnostic accuracy of teledermoscopic assessors that had access to the results of artificial intelligence algorithm compared to those who did not.
Data will be collected through teledermoscopic referrals, patient records, national registries and questionnairs.
Detailed description
Study objective:
- Is teledermoscopy an equally safe method as conventional care for skin cancer patients? 2. How should teledermoscopy be performed and by whom? 2. How does teledermoscopy affect current care and organization of skin diseases? 3. Can deep learning AI improve diagnostic accuracy by being a diagnostic support to dermatologists? 4. How should AI be implemented in care pathways for optimal interaction between assessors and AI?
Material and methods:
- Study setting Patients scheduled for a skin examination for a suspected skin lesion can be recruited, both in dermatology clinics and participating primary care clinics or digitally after visiting primary health clinics.
- Data acquisition Patient data and images will be collected with the Dermicus® application. Participating PCP and dermatologists will also fill in a questionnaire about their assessment of the patient. Additional informaiton will be collected from medical records, i.e. histopathological diagnoses, and from national registries. Questionnaires will be entered in a digital data base using REDCap®.
- Statistical analyses 4.1. In part 1, the number of consultations send to dermatologists and for pathological analyses before introduction of teledermoscopy and during the first and second year if using teledermoscopy will be analysed. Descriptive statistics will be presented and differences between the different time periods will be tested with t-tests and paired t-tests.
Additionally, other aspects of teledermatology will be examined, such as the impact on diagnostic accuracy of performing double-reader instead of singe-reader assessments as well as the propensity in primary care physicians to perform total body skin examinations when using teledermoscopy instead of traditional referals to dermatologists for the assessment of skin lesions.
4.2. Also part 2 has several substudies which focus on the impact of diagnostic accuracy and clinical management when introducing AI that perform different tasks in the teledermocopy work flow. For example, one AI will be trained to categorise all skin lesions referred through teledermoscopy in eight diagnostic categories and another will be looking at finer-grained diagnostic classes, such as subclassification of basal cell carcinoma.
Measures of diagnostic accuracy will be estimated comparing dermatologists with and without access to diagnostic algorithm support. Measures reported include sensitivity, specificity, and Area under ROC-curve (AUROC). Part 2 The study will also report in detail the impact the AI has on the willingness to change a diagnosis or a management plan (in all directions).
Generalized linear mixed-effects models (GLMMs) with a binomial distribution and logit link function will be used to assess the impact of AI assistance on diagnostic accuracy and management decisions. The models will include AI assistance, patient age, sex, and diagnostic confidence as fixed effects, with random intercepts for individual assessors to account for clustering of observations within assessors.
- Power set to 0.8 and significance to 0.05. 10% censures. 5.1. Patients recruited to this study can be used in several of the sub-studies. The aim of the study is to collect 8000 patients in total in this study.
5.2. To detect a difference in "unimaged skin cancers" between teledermoscopy and conventional care of patients 1200 cases and 2400 controls need to be included.
5.3. To detect a 10% difference in sensitivity/ specificity of diagnostic ability in PCPs before and after working with teledermoscopy 3400 patients need to be included.
5.4. To investigate how artificial intelligence should be implemented in clinical care the investigators have calculated that 6000 patients are needed to detect a 10% difference in sensitivity and specificity in the subgroups.
Ethical considerations and data management:
Data will be collected using Dermicus®, a CE-certified digital platform and mobile application. With the application downloaded on iPhones®, locked for any other uses, the history of the patients are registered. Then, by connecting the iPhone to a dermoscope, macroscopic and dermoscopic images are captured. All data will be stored on the servers of the health care region of Skåne, where the studies are conducted. Once a case has been created and sent to the data base all information will be deleted from the iPhone®. Additional data will also be retrieved from relevant medical records, e.g. histopathological diagnosis, and manually registered in an electronic database at a highly secure location (LUSEC/ REDCap provided by Lund University/ ShareFile provided by Region Skåne) . Data collected from PCP and dermatologists by questionnaires will also be registered in this data base by means of electronic surveys (REDCap). Information from primary care on total number of visits, referrals to dermatologists and referrals to pathology regarding skin lesions will be extracted from patient administrative systems. Age- and sex matched controls will be used for the study investigating missed skin cancer. These controls will be randomly selected from patients that was referred to a skin clinic by paper referral during the same period as the teledermoscopically referred patients were gathered. Algorithms for skin cancer diagnosis will be implemented in the web platform of Dermicus for the studies of introduction of artificial intelligence. Teledermoscopic assessors will be instructed on when and how to use these different tools.
Every month the newly entered data will be checked for completeness, and in the case of missing data, reminders to participating investigators will be send.
When the data sets are complete, identifiers (such as personal identification number) will be replaced by a code kept secure at a different location than the data set. Data will thereafter be extracted from the data base to perform statistical analysis.
The study is approved by the Swedish Ethical Review Authority and all relevant approvals for data extraction and data storage has been obtained.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 8 Years
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients, 15 years or older, seeking care for a suspected skin lesion, or when a suspected skin lesion is detected during a visit for another complaint, for whom a teledermoscopic consultation is created.
Key inclusion criteria (2 listed)
- Has a skin lesion assessed by a physician during a visit
- The physician decides to create a teledermoscopy referral
Key exclusion criteria (3 listed)
- inability or unwillingness to participate in the study
- the patient is younger than 15 years old
- Images of such bad quality they cannot be assessed
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic algorithmsAssessors of teledermoscopy will be randomly assigned to use the results of artificial intelligence when the assess a teledermoscopic case. | Device | – |
Primary outcome
Effect on referral patterns
Time frame: 2 years
Measure how referral patterns are affected by the introduction of teledermoscopy
Effect on diagnostic accuracy due to availability of artificial intelligence
Time frame: 8 years
Measuring if the diagnostic accurcy differs depending on if physician can see the results of the artificial intelligence.
Risk of undetected skin cancer
Time frame: 2 years
Measuring if the risk of undetected skin cancer increases with the use of teledermoscopy
Artificial intelligence timing and effect on diagnostic accuracy and willingness to rethink the preliminary diagnosis
Time frame: 8 years
Measuring if the diagnostic accuracy and the willingness to reconsider the preliminary diagnosis differs according to when in the process a physician is presented with the results of the artificial intelligence
2 secondary outcomes
Image enhancement techniques in teledermoscopy
Time frame: From 2021 to 2025
When single reader evaluations are insufficient in teledermoscopy
Time frame: 2021-2024
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Derived from this study: PubMed 39869017Natterdahl C, Kristensson H, Persson B, Lapins J, Ivert LU, Radros N, Schultz K, Sand C, Lundgren S, Pahlow Mose A, Ingvar J, Dizdarevic A, Nielsen K, Ingvar A. When Are Single Reader Evaluations Insufficient in Teledermoscopic Assessments? Analyses of a Retrospective Cohort Study. Telemed J E Health. 2025 May;31(5):579-589. doi: 10.1089/tmj.2024.0532. Epub 2025 Jan 27.
- Individual participant dataSharing planned: No
Related trials for Skin Cancer
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Enrolling by invitationObservational study
Community Based Strategies for Early Detection of Melanoma
Melanoma
Active, not recruitingPhase 3
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
RecruitingPhase 1/2
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Breast Cancer
Not yet recruiting
Podcast-Based Psychosocial Support for Women Newly Diagnosed With Breast Cancer
Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Asa Ingvar, PhD principal investigator
Department of Dermatology, Skane University Hospital, Region Skane, Sweden
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Skin Cancer, run by Region Skane at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Asa Ingvar, PhD (+4646172243, asa.ingvar@skane.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Effect on referral patterns (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05033678, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.